"
Header
Nowadays when people get sick they ingest a pill or get an intravenous injection to combat the pathogens. The drug gets distributed throughout the entire body of the patient, and can cause severe side effects. The idea of targeted drug delivery is to increase the concentration of the drug at the target site while keeping it to a minimum in the rest of the organism. Such specific drug delivery can be used to treat various diseases, especially tumor, whether benign or malignant, or ulcers. In theory, the side effects of the drugs would be less severe. Especially spikes of drugs in the blood system would be avoided in treatements like chemotherapy. Furthermore the amount of drugs that have to be ingested could be reduced. One big drawback of targeted drug delivery is that it doesn’t exist for many drugs, it needs to be developed for each drug separately and that is obviously quite expensive.
Introduction
Our team aims to create a highly adaptable smart drug delivery system, which could be used for several applications and alternatives in disease treatment. The design makes it so flexible that it could even be possible to adapt it to the patient’s individual needs. By being highly adaptive, the system we propose would also reduce the cost of targeted drug delivery because instead of creating a new system for each drug and each patient, one could simply use the basic part that we made, modify them slightly and assemble them. This sort of "Parts recycling" would not only be economical but also ecological.
Given the limited time we only wanted to make a proof of principle. We used E.coli as model organism. Using the principles of synthetic biology we aimed to engineer an E.coli Bacterium that expresses streptavidin on their surface and contains a pH sensing promoter that controls the expression of gelatinases. Those bacteria would be able to bind biotinylated nanoparticles.
The nanoparticles are made out of gelatine, this kind of nanoparticles has been shown to be able to transport xxy. They were biotinylated using activated biotin. We invite you to read more about nanoparticles. To assemble the nanoparticles with the bacteria, they only need to be in the same tube, because the interaction between the biotin and streptavidin is very strong.
To make the bacteria express streptavidin on their surface, we engineered a plasmid that encodes a fusion protein between streptavidin and ice nucleation protein from pseudomonas syringae, which serves as an anchor for the streptavidin to the outer membrane. Read more about this part of the project. At this point the bacteria would be able to transport a nanoparticle, but on its own this wouldn’t make any sense.
The crucial point of our project is that E.coli was genetically engineered to sense changes in pH or arabinose. Read more about sensing. Sensing this changes triggers the production of enzymes that degrade the nanoparticles, GelE gelatinase from Enterococcus Fecalis and Matrix Metalloprotease MMP2 from H. Sapiens. So the drug will be released exactly where it is needed to treat the patient.
As mentioned before we only aimed to make a proof of principle, eventually it would be necessary to develop the system in another organism, to add safety mechanisms, and develop different sensing plasmid. Read more the future applications we imagine.
